By Delilah Alvarado
Published August 27, 2026
AstraZeneca and Amgen have announced a significant clinical milestone for their monoclonal antibody, Tezspire (tezepelumab), which successfully met all primary and secondary endpoints in a pivotal Phase 3 study for the treatment of eosinophilic esophagitis (EoE). This positive data readout marks a potential third major indication for the therapy, further cementing its role as a cornerstone asset in both companies’ respiratory and immunology portfolios.
As the pharmaceutical landscape increasingly pivots toward precision medicine for chronic inflammatory conditions, the success of the "CROSSING" trial positions Tezspire as a formidable challenger in the competitive EoE market, currently dominated by established biologics.
The Core Clinical Achievement
The Phase 3 CROSSING trial evaluated the efficacy and safety of Tezspire in patients suffering from eosinophilic esophagitis—a chronic, immune-mediated disease characterized by the infiltration of white blood cells (eosinophils) into the esophageal lining. This buildup triggers inflammation, leading to severe swallowing difficulties, food impaction, and long-term tissue damage.
According to the joint statement issued by the partners on Thursday, the treatment arm demonstrated "statistically significant and clinically meaningful improvements" across all primary objectives. These improvements were measured not only by histological markers—the reduction of eosinophil counts in the esophagus—but also by patient-reported symptoms of disease severity. Notably, the therapeutic effects observed at the 24-week mark were sustained throughout the full one-year study duration, suggesting a robust and durable response profile.
While the companies have withheld granular data for an upcoming medical conference, the announcement provides a clear signal to both regulators and investors: Tezspire is poised to expand its reach well beyond its current applications.
A Chronology of Tezspire’s Clinical Evolution
Tezspire’s journey to becoming a billion-dollar product has been defined by a strategic, step-by-step expansion into high-unmet-need inflammatory diseases.
- Initial Approval (2021): The FDA first granted approval to Tezspire as an add-on maintenance treatment for adult and pediatric patients aged 12 and older with severe asthma. As a first-in-class thymic stromal lymphopoietin (TSLP) blocker, it provided a novel mechanism of action that targets the upstream source of inflammation rather than specific downstream pathways.
- Expansion into Chronic Rhinosinusitis (2025): Building on its asthma success, the drug secured a label expansion for chronic rhinosinusitis with nasal polyps, further validating its utility in Type 2 inflammatory disorders.
- The Eosinophilic Esophagitis Pursuit (2026): The successful completion of the Phase 3 EoE trial represents the latest chapter in the drug’s development. Following this win, the partners have committed to submitting these results to global regulatory authorities, including the FDA and the European Medicines Agency (EMA), later this year.
Supporting Data and Market Dynamics
Tezspire is no longer merely a promising candidate; it has firmly entered the "blockbuster" category of drugs—those generating over $1 billion in annual revenue.
Financial disclosures from the last fiscal year highlight the drug’s rapid trajectory. Both AstraZeneca and Amgen reported annual sales exceeding the $1 billion threshold in 2025. This growth momentum has continued into 2026, with AstraZeneca recording $390 million in the second quarter alone—a 45% surge compared to the same period in 2025.
The EoE Opportunity
The market for eosinophilic esophagitis is ripe for innovation. Current standard-of-care treatments, such as proton pump inhibitors (PPIs) and topical swallowed corticosteroids, often fail to provide relief for a significant portion of the patient population. AstraZeneca estimates that approximately 50% of patients remain symptomatic or refractory to these initial therapies.
William Blair analyst Matt Phipps noted that with over 470,000 affected individuals in the United States alone, the prevalence of the disease is on an upward trend. "These factors support an attractive third indication for Tezspire with blockbuster potential," Phipps wrote in a recent client note. The ability of Tezspire to offer a novel TSLP-blocking mechanism for these "non-responders" provides a compelling value proposition for gastroenterologists and patients alike.
Official Responses and Strategic Perspectives
Leadership from both organizations emphasized that this trial result is a testament to the drug’s versatility.
"We are encouraged by the sustained, significant improvement in clinical symptoms and histological markers," said a representative for the development team. "Tezspire’s unique ability to act at the top of the inflammatory cascade allows us to address the diverse needs of patients suffering from a range of TSLP-driven diseases."
For Amgen, which holds the U.S. commercialization rights, Tezspire is a vital component of its broader growth strategy. The company is currently balancing its existing revenue drivers—including products like Uplizna, Imdelltra, and the cholesterol-lowering Repatha—with high-stakes research into the next generation of obesity therapies. A successful launch in the EoE space would provide the company with stable, long-term cash flow to support these R&D investments.
Implications: A New Battlefield in Immunology
The impending move into the EoE space sets the stage for a high-profile showdown between some of the industry’s most powerful biologic franchises.
Direct Competition with Dupixent
Should Tezspire receive regulatory clearance for EoE, it will face direct competition from Sanofi and Regeneron’s Dupixent (dupilumab). Dupixent has already established itself as a dominant force in immunology, and both companies have identified EoE as a "meaningful growth driver" for their respective balance sheets.
The competition will likely hinge on three key factors:
- Dosing Regimen: Ease of administration and the frequency of treatment will be critical for long-term patient adherence in a chronic condition like EoE.
- Breadth of Clinical Data: Physicians will scrutinize how Tezspire’s TSLP-blocking mechanism compares to the IL-4 and IL-13 blockade of Dupixent in terms of long-term tissue remodeling and symptom control.
- Market Access: The ability of AstraZeneca and Amgen to secure favorable formulary placement and payer coverage will be decisive in capturing market share from an incumbent.
Impact on AstraZeneca’s $80 Billion Goal
For AstraZeneca, this win is a crucial building block in its ambitious roadmap to reach $80 billion in annual revenue by 2030. CEO Pascal Soriot has consistently pointed to the company’s "pipeline in a product" strategy—whereby a single molecule like Tezspire is tested across multiple indications to maximize return on investment. By moving Tezspire from a respiratory-focused drug to a multi-disciplinary immunology staple, AstraZeneca is successfully de-risking its long-term growth targets.
Conclusion: The Path Ahead
The success of the Phase 3 study in eosinophilic esophagitis is a significant validation of the clinical strategy pursued by AstraZeneca and Amgen. While the regulatory review process lies ahead, the data presents a strong case for a new standard of care for a population that has been historically underserved.
As the industry prepares for the formal data presentation at upcoming medical meetings, the focus will shift to how these results translate into real-world clinical practice. If approved, Tezspire will not only provide a vital new option for EoE patients but also solidify its status as a foundational pillar in the treatment of chronic inflammatory diseases, further entrenching the competitive landscape of modern biotechnology.
For investors and patients alike, the next 18 months will be transformative, as the companies move to secure the approvals necessary to turn this clinical success into a market-ready reality.
About the Author
